Zemdri
Manufacturing · United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
United StatesWebsite
www.zemdri.comRevenue
<$5 MillionIndustry
About Zemdri
Cipla USA, Inc. offers ZEMDRI® (plazomicin) injection, a treatment specifically indicated for adult patients with complicated urinary tract infections (cUTI), including pyelonephritis, caused by certain susceptible microorganisms. The product is designed for healthcare professionals in the United States, focusing on patients who have limited or no alternative treatment options. Cipla Therapeutics collaborates with Tanner Pharma Group to manage access requests for plazomicin in countries outside the U.S. The company emphasizes the importance of monitoring for potential adverse effects associated with the drug, including nephrotoxicity and ototoxicity.Explore more
SIC Code 28,283NAICS Code 32,325Show moreZemdri Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Zemdri
Compare insights from companies similar to Zemdri, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Zemdri Tech Stack
A closer look at the technologies used by Zemdri
See more technologies
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Zemdri
Sign Up For FreeTo access detailed company insights
Cipla USA, Inc. offers ZEMDRI® (plazomicin) injection, a treatment specifically indicated for adult patients with complicated urinary tract infections (cUTI), including pyelonephritis, caused by certain susceptible microorganisms. The product is designed for healthcare professionals in the United States, focusing on patients who have limited or no... Read More
